Chem Financing to Remain Challenged (ICIS Chemical Business August 18 – August 24, 2023)Jonathan Choi2023-09-18T19:55:08+00:00August 24th, 2023|Featured, Our Publications|
Chemical M&A Activity Turns Up (ICIS Chemical Business August 11 – August 17, 2023)Jonathan Choi2023-09-18T19:55:40+00:00August 11th, 2023|Featured, Our Publications|
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)Jonathan Choi2023-03-14T19:28:18+00:00March 14th, 2023|Featured, Our Publications|
Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)Jonathan Choi2023-02-08T02:20:40+00:00February 3rd, 2023|Featured, Our Publications|
Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)Jonathan Choi2023-01-26T15:10:20+00:00January 20th, 2023|Featured, Our Publications|
Young & Partners Chemical M&A Review and Outlook (January 17, 2023)Jonathan Choi2023-01-26T15:10:48+00:00January 17th, 2023|Featured, Our Publications|
Disruptions to hit M&A, financing (ICIS Chemical Business December 2 – December 8, 2022)Jonathan Choi2023-01-26T15:01:39+00:00December 2nd, 2022|Featured, Our Publications|
Chemical M&A trends shift down (ICIS Chemical Business August 26 – September 1, 2022)digitalstudios2022-08-28T14:56:04+00:00August 26th, 2022|Featured|
Pharm Exec: Navigating the Financial Meltdown for Biopharma (Young & Partners article – August 2022 issue)digitalstudios2022-08-12T18:23:33+00:00August 12th, 2022|Featured|
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)Devin Maraj2022-04-12T16:14:36+00:00April 12th, 2022|Featured, Our Publications|
